Stock VIVOBIOT6 VIVO BIO TECH LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Vivo Bio Tech Limited

Equities

VIVOBIOT6

INE380K01017

Biotechnology & Medical Research

Market Closed - Bombay S.E.
Other stock markets
 06:00:52 2024-05-28 am EDT 		5-day change 1st Jan Change
40.11 INR -3.51% Intraday chart for Vivo Bio Tech Limited -4.50% +21.18%
May. 20 Vivo Bio Tech Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
May. 20 Vivo Bio Tech Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 520.8 684.2 250 635.6 565.5 287.6
Enterprise Value (EV) 1 730.5 895.4 483.4 933.5 1,223 897.8
P/E ratio 17.6 x 26.5 x 5.63 x 11.3 x 25.5 x 10.8 x
Yield - - - - - -
Capitalization / Revenue 1.11 x 1.23 x 0.45 x 1.23 x 1.1 x 0.55 x
EV / Revenue 1.55 x 1.6 x 0.87 x 1.8 x 2.38 x 1.72 x
EV / EBITDA 6.74 x 9.36 x 4 x 5.57 x 8.55 x 4.63 x
EV / FCF 95.3 x -14.7 x -11.7 x -7.79 x -3.13 x 47.8 x
FCF Yield 1.05% -6.82% -8.54% -12.8% -31.9% 2.09%
Price to Book 2.84 x 2.51 x 0.76 x 1.51 x 1.2 x 0.55 x
Nbr of stocks (in thousands) 9,351 12,351 12,888 13,270 14,264 14,904
Reference price 2 55.70 55.40 19.40 47.90 39.65 19.30
Announcement Date 8/29/18 9/3/19 9/5/20 9/6/21 9/6/22 9/8/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 470 558.3 553.5 517.8 513.9 522.3
EBITDA 1 108.3 95.68 121 167.6 143 194
EBIT 1 62.4 45.33 72.99 120.7 83.67 122.4
Operating Margin 13.28% 8.12% 13.19% 23.31% 16.28% 23.43%
Earnings before Tax (EBT) 1 40.06 18.25 42.53 86.2 44.72 46.21
Net income 1 31.21 22.48 44.42 56.82 22.02 26.49
Net margin 6.64% 4.03% 8.02% 10.98% 4.28% 5.07%
EPS 2 3.169 2.090 3.446 4.230 1.557 1.780
Free Cash Flow 1 7.666 -61.09 -41.28 -119.8 -390.4 18.8
FCF margin 1.63% -10.94% -7.46% -23.13% -75.96% 3.6%
FCF Conversion (EBITDA) 7.08% - - - - 9.69%
FCF Conversion (Net income) 24.56% - - - - 70.95%
Dividend per Share - - - - - -
Announcement Date 8/29/18 9/3/19 9/5/20 9/6/21 9/6/22 9/8/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 210 211 233 298 657 610
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 1.935 x 2.207 x 1.929 x 1.777 x 4.596 x 3.145 x
Free Cash Flow 1 7.67 -61.1 -41.3 -120 -390 18.8
ROE (net income / shareholders' equity) 19.6% 9.65% 14.7% 15% 4.91% 5.35%
ROA (Net income/ Total Assets) 7.05% 4.94% 7.67% 10.5% 5.18% 6.23%
Assets 1 442.7 454.6 579.4 539.3 425.2 425.2
Book Value Per Share 2 19.60 22.10 25.60 31.70 33.00 34.80
Cash Flow per Share 2 4.210 0.4600 0.8000 0.8700 1.200 0.9200
Capex 1 47.2 35.3 102 228 511 40
Capex / Sales 10.04% 6.32% 18.49% 44.08% 99.46% 7.65%
Announcement Date 8/29/18 9/3/19 9/5/20 9/6/21 9/6/22 9/8/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
VIVO BIO TECH LIMITED Stock Vivo Bio Tech Limited
+21.18% 7.45M
MODERNA, INC. Stock Moderna, Inc.
+54.05% 63.85B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-2.02% 41.83B
LONZA GROUP AG Stock Lonza Group AG
+40.01% 40.47B
CELLTRION, INC. Stock Celltrion, Inc.
-10.22% 27.17B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.42% 26.52B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.60% 18.69B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+2.89% 12.73B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+22.40% 12.11B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.49% 12.07B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. VIVOBIOT6 Stock
  4. Financials Vivo Bio Tech Limited